Study the Effects of CYP2C Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide

This study has been completed.
Information provided by:
Chinese Academy of Sciences Identifier:
First received: December 9, 2008
Last updated: January 26, 2010
Last verified: December 2008

The aims of this study were to investigate the effects of CYP2C9 and CYP2C19 polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in healthy Chinese subjects.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Study the Effects of CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Glipizide in Healthy Chinese Subject

Resource links provided by NLM:

Further study details as provided by Chinese Academy of Sciences:

Biospecimen Retention:   Samples With DNA

The whole blood samples of each person are stored at -80℃.

Enrollment: 36
Study Start Date: August 2008
Study Completion Date: December 2008
CYP2C9*1/*1 and CYP2C19*1/*1 alleles carrier
CYP2C19 PMs (CYP2C19*2/*2, CYP2C19*2/*3 or CYP2C19*3/*3)
CYP2C9*1/*3 and CYP2C19*1/*1 alleles carrier

Detailed Description:

Compared with CYP2C19, CYP2C9 polymorphism appears to have a dominant role in glipizide pharmacokinetics and pharmacodynamics in vivo. This indicated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treatment.


Ages Eligible for Study:   21 Years to 27 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Male Chinese subjects with different geontype of CYP2C9 and CYP2C19 were enrolled in this study. They are divided into three groups by different geontype.


Inclusion Criteria:

  • nonsmokers and in good health

Exclusion Criteria:

  • family history of diabetes mellitus
  • taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study
  Contacts and Locations
Please refer to this study by its identifier: NCT00806013

China, Liaoning
The second hospital to Liaoning University of TCM
Shenyang, Liaoning, China, 201203
Sponsors and Collaborators
Chinese Academy of Sciences
Principal Investigator: Bo Tan Shanghai Institute of Materia Medica
  More Information

Additional Information:
No publications provided Identifier: NCT00806013     History of Changes
Other Study ID Numbers: SIMM-080601
Study First Received: December 9, 2008
Last Updated: January 26, 2010
Health Authority: China: National Natural Science Foundation

Keywords provided by Chinese Academy of Sciences:

Additional relevant MeSH terms:
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions processed this record on April 16, 2014